Skip to main content
. Author manuscript; available in PMC: 2022 Jan 4.
Published in final edited form as: Mol Pharm. 2020 Dec 15;18(1):214–227. doi: 10.1021/acs.molpharmaceut.0c00831

Figure 8.

Figure 8.

Efficacy of ICV ERT in MPS IIID mice with rhGNS. A) The amount of heparan sulfate in the mouse brain 7 days following a single dose of 67 units, Gns+/− VEH (n=6), Gnsr−/− VEH (n=5), Gnsr−/− ENZ (n=5). B, C) β-hexosaminidase activity in mouse brain lysate 3 and 7 days after treatment. Gns+/− VEH (n=4), Gns−/− VEH (n=5), Gns−/− ENZ (n=5) for day 3 and Gns+/− VEH (n=6), Gns−/− VEH (n=5), Gns−/− ENZ (n=5) for day 7. Data are shown as mean ± SD, and individual animal means are indicated by symbols. Statistical analysis was performed using one-way ANOVA. * * p < 0.05, *** p < 0.001.